Elanco Animal Health to Invest $130M in KS Facility, Plans 70 New Jobs

Posted August 21, 2024

Elanco Animal Health Inc. will invest $130 million in its manufacturing facility in Elwood for renovations and approximately 70 new jobs.

Through the end of 2026, Elanco plans to expand and renovate its Elwood site, which manufactures dog treatment medicine such as its Canine Parvovirus Monoclonal Antibody. The expansion will create approximately 70 new jobs over the next two years, according to a release from the Kansas City Area Development Council.

Elanco is a part of the KC Animal Health Corridor, a concentration of more than 300 animal health companies in the region, which accounts for 56% of global animal health, diagnostics and pet food sales, according to the KCADC.

The KC Animal Health Corridor is an affiliate of the KCADC.

“Elanco Animal Health’s investment in its Kansas facility furthers its commitment of innovation from the center of the global animal health industry,” Kimberly Young, president of the KC Animal Health Corridor, said in the release.

Kansas City-based Burns & McDonnell will lead the expansion project’s design and construction services.